Medium materiality6/10
Oppenheimer raises ArriVent Biopharma price target to $25
Why it may matterVerify against the original reporting
Bullish analyst revision, though target estimates are uncertain.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Oppenheimer raised its AVBP price target from $18 to $25; the posted share price was $15.36, leaving the new target about 63% above that price. Analyst targets are opinions, so this is a positive but not definitive signal.
- Target raised from $18 to $25; posted price $15.36.
Key facts
- 01
Target: $25
- 02
Posted price: $15.36
- 03
Analyst firm: Oppenheimer
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.